Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Hana Micron (067310) – Additional Listing (Exercise of Stock Options) / 2026-07-16

Posted on July 16, 2026August 2, 2026 By K-STOCK Editor No Comments on [Disclosure] Hana Micron (067310) – Additional Listing (Exercise of Stock Options) / 2026-07-16

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Hana Micron will issue and list 10,443 new common shares following the exercise of stock options.

📊 [Key Disclosure Contents & Summary Metrics]

1. Additional Listing Overview

  • Disclosure Type: Additional Listing (Exercise of Stock Options)
  • Company Name: Hana Micron Co., Ltd.
  • Listing Date: July 22, 2026
  • Type and Number of Additional Shares: 10,443 Common Shares
  • Par Value per Share: KRW 500
  • Total Issued Shares Post-Listing: 66,490,869 Common Shares
  • Dividend Accrual Date for New Shares: January 1, 2026

2. Details of Stock Option Exercise

  • 3,000 Common Shares: Exercise Price KRW 8,065 (19th Tranche, Exercise Date: July 3, 2026)
  • 7,443 Common Shares: Exercise Price KRW 16,218 (21st Tranche, Exercise Date: July 2, 2026)

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Increase in Outstanding Shares and Stock Dilution Effect

This disclosure indicates an increase in total outstanding shares as a total of 10,443 new common shares are newly listed following stock option exercises. Reviewing the ratio of newly listed shares relative to total outstanding shares and their listing timeline is important for assessing potential equity dilution and liquidity changes in the market. Relevant updates can be verified under the “Total Number of Shares” and “Status of Grant and Exercise of Stock Options” sections in subsequent Regular Business Reports.

📢 Disclaimer and Source Information

Source: This content was structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the individual investor.

Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Semiconductors

Post navigation

Previous Post: [Disclosure] Hyundai Motor (005380) – Notice of Investor Relations (IR) Earnings Release for Q2 2026
Next Post: [Disclosure] Daeduck Electronics (353200) – Advance Notice of Earnings Release / 2026-07-16

Related Posts

[Disclosure] Jusung Engineering (036930) – Notice of New Listing of Stock Futures and Options (Listing of New Contract Months for Stock Futures Following Withdrawal of Corporate Spin-off) / 2024-11-14 Semiconductors
[Disclosure] Hanwha Ocean (042660) Announces Board Decision to Absorb 100% Owned Subsidiary Hanwha Ocean Digital Disclosures
[Disclosure] Hanwha Ocean (042660) – (Correction) Rights Issue Decision / 2025-08-07 Disclosures
[Disclosure] Samsung Electro-Mechanics (009150) – Publication of Sustainability Report (Voluntary Disclosure) / 2025-06-30 Semiconductors
[Disclosure] SK Hynix (000660) – Other Management Decisions (Voluntary Disclosure) / 2024-12-16 Disclosures
[Disclosure] Hanmi Semiconductor (042700) – Investor Relations (IR) Holding / 2026-02-23 Semiconductors

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme